Search Patents
  • Aralkylaminoethanol heterocyclic compounds
    Patent number: 4686222
    Abstract: Heterocyclic aminoethanols of the formulaHet--CHOH--CH.sub.2 --NH--aralkylwhere het is a 6-10 membered N heterocycle are disclosed. The compounds are useful as pharmaceuticals.
    Type: Grant
    Filed: October 3, 1985
    Date of Patent: August 11, 1987
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme (I.A.) Corp.
    Inventors: Joseph G. Atkinson, John J. Baldwin, David E. McClure
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20130187092
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy, which contains at least one compound of the formula I and at least one compound of the formula II in which R1, R2, R3, R4, ring A, Z1, Z2 and m are as defined in Claim 1, and to the use thereof for an active-matrix display based on the ECB, VA, PS-VA, FFS, PALC or IPS effect.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 25, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
  • 11-hydroxysordarin and a process for producing it using actinomyces SSP
    Patent number: 6228622
    Abstract: 11-hydroxysordarin, biotransformation product of a fermentation with sordarin and Actinomyces spp., (Merck Culture Collection MA7235) ATCC No. 202103 is an antifungal agent. This compound may be useful in the treatment of diseases caused by fungal pathogens such as Candida albicans.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: May 8, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Michael G. Sturr, Michel M. Chartrain, Guy H. Harris, Jennifer Nielsen-Kahn, Brian Heimbuch
  • RORgammaT inhibitors
    Patent number: 9095583
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 4, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • ? v integrin receptor antagonists
    Patent number: 7288655
    Abstract: The present invention relates to the synthesis of intermediates for the preparation of compounds of formula (A): wherein n is 2 or 3 and various salt forms of these compounds.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: October 30, 2007
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Brian Christopher Bishop, Karel Marie Joseph Brands, Ian Frank Cottrell, Cameron John Cowden, Antony John Davies, Stephen Philip Keen, David Ross Lieberman, Gavin William Stewart
  • RORgammaT inhibitors
    Patent number: 9884043
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 6, 2018
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 5-lipoxygenase activating protein
    Patent number: 5182367
    Abstract: An 18kD protein (FLAP) has been isolated from rat and human cells which is necessary for production of leukotrienes from arachidonic acid in mammalian cells containing 5-lipoxygenase. The gene (cDNA) encoding for FLAP has also been produced.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: January 26, 1993
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Jacques-Yves Gauthier, Jillian F. Evans, Rejean Fortin, Yvan Guinon, Richard A. F. Dixon, Douglas K. Miller
  • PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS
    Publication number: 20140107346
    Abstract: A process for the preparation of pyrazolopyrolidines of structural formula I: and W is or P, wherein in P is an amine protecting group. These compounds are useful in the synthesis of dipeptidyl peptidase-IV inhibitors for the treatment of Type 2 diabetes. Also provided are useful intermediates obtained from the process.
    Type: Application
    Filed: June 25, 2012
    Publication date: April 17, 2014
    Applicants: Merck Sharp & Dohme Ltd., Merck Sharp & Dohme Corp.
    Inventors: Michael J. Zacuto, Robert F. Dunn, Aaron J. Moment, Jacob M. Janey, David Lieberman, Faye Sheen, Nadine Bremeyer, Jeremy Scott, Jeffrey T. Kuethe
  • PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION
    Publication number: 20130171714
    Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).
    Type: Application
    Filed: January 16, 2013
    Publication date: July 4, 2013
    Applicant: MERCK SERONO SA
    Inventor: MERCK SERONO SA
  • Mitotic kinesin inhibitors
    Patent number: 7745639
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: June 29, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, J. Christopher Culberson, George D. Hartman, Brenda J. Mariano, Maricel Torrent
  • Formulation for parenteral administration
    Patent number: 11077050
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 3, 2021
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • Process for the preparation of an orexin receptor antagonist
    Patent number: 9108959
    Abstract: The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: August 18, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Carl A. Baxter, Edward Cleator, Faye Sheen, Shane W. Krska, Gavin Stewart, Neil Strotman, Debra J. Wallace, Timothy Wright
  • FORMULATION FOR PARENTERAL ADMINISTRATION
    Publication number: 20200289406
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Application
    Filed: March 19, 2018
    Publication date: September 17, 2020
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B. V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
    Publication number: 20130157940
    Abstract: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 20, 2013
    Applicant: Merck Sharp & Dohme Corp
    Inventor: Merck Sharp & Dohme Corp
  • Piperdine Glycine Transporter Inhibitors
    Publication number: 20090270451
    Abstract: The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Application
    Filed: October 27, 2006
    Publication date: October 29, 2009
    Applicants: MERCK & CO., INC., MERCK SHARP & DOHME LIMITED
    Inventors: David Hallett, Craig W. Lindsley, Elizabeth M. Naylor, Zhijian Zhao, Cory R. Theberge, Scott E. Wolkenberg, M. Brad Nolt
  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    Patent number: 6740666
    Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 25, 2004
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Dwight Macdonald, Helene Perrier, Roch Thibert, Guo-Jie Ho, Anant Vailaya, David Conlon, Elizabeth Kwong, Sophie-Dorothee Clas
  • Transgenic mouse having a disrupted amyloid precursor protein gene
    Patent number: 6187992
    Abstract: The present invention relates to a transgenic nonhuman animal lacking native amyloid precursor protein. The transgenic mouse of the invention may be used in the study of Alzheimer's Disease and disorders involving the central nervous system.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: February 13, 2001
    Assignees: Merck & co., Inc., Merck Frosst Canada & Co.
    Inventors: Hui Zheng, Howard Y. Chen, Myrna E. Trumbauer, Leonardus H. T. van der Ploeg, Guy Seabrook, Dalip Sirinathsinghji
  • NAV1.7 BINDERS
    Publication number: 20240002497
    Abstract: Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7? protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).
    Type: Application
    Filed: November 18, 2021
    Publication date: January 4, 2024
    Applicants: MERCK SHARP & DOHME LLC, MERCK SHARP & DOHME RESEARCH GMBH
    Inventors: Pravien Damitha Abeywickrema, Erik Depla, Bruno Dombrecht, Daniel M. Gorman, Andrea K. Houghton, Robert A. Kastelein, Richard L. Kraus, John Majercak, Kalyan Pande, Sujata Sharma
  • 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
    Patent number: 4377588
    Abstract: Novel 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.
    Type: Grant
    Filed: September 11, 1979
    Date of Patent: March 22, 1983
    Assignees: Merck Sharp & Dohme (I.A.) Corp., Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney, Haydn W. R. Williams
  • Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
    Patent number: 7629467
    Abstract: The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: December 8, 2009
    Assignees: Merck & Co., Inc., Merck Frosst Canada Ltd
    Inventors: Lin Chu, Mark T. Goulet, Feroze Ujjainwalla, Linda Chang, Richard Frenette, Yves Girard, Michel Therien, Dwight Macdonald, John H. Hutchinson
Narrow Results

Filter by US Classification